ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
To evaluate the clinical efficacy and safety of Almonertinib in EGFR-mutant advanced NSCLC patients with different nutritional statuses. Clinical data from 56 patients with advanced EGFR-mutant NSCLC admitted to the First Affiliated Hospital of Anhui Medical University from April 2021 to April 2023 were retrospectively analyzed. Patients were stratified into two groups based on nutritional risk (nutritional risk group, n = 30; non-risk group, n = 26) and into two groups based on malnutrition status (malnutrition group, n = 35; regular nutrition group, n = 21). Kaplan-Meier methods were used to plot survival curves, the Chi-square test was employed to evaluate clinical efficacy, and Cox regression analysis was applied to identify factors associated with adverse reactions. Patients in the nutritional risk group had a median progression-free survival (mPFS) of 12.8 months (95% CI: 9.146-16.454), which was shorter than that of the non-risk group (mPFS: 19.7 months; 95% CI: 12.234-27.166), showing statistical significance (P = 0.049). However, there was no significant difference in median overall survival (mOS) between the two groups (P = 0.546). In the malnutrition group, patients had an mPFS of 12.6 months (95% CI: 9.648-15.552) and an mOS of 29.8 months (95% CI: 24.476-35.124), both significantly shorter than those of the regular nutrition group (mPFS: 19.7 months, 95% CI: 13.097-26.303; mOS: 32.1 months, 95% CI: 23.781-40.419) (P = 0.034 and P = 0.046, respectively). There was no significant difference in objective response rate (ORR) between groups (P > 0.05). Serum albumin levels were independently associated with the incidence of adverse reactions (P = 0.003; HR: 7.194, 95% CI: 1.925-26.886). Almonertinib demonstrates favorable efficacy and safety in treating advanced NSCLC patients with malnutrition or nutritional risk accompanying EGFR mutations. The shortened PFS observed in cachectic patients may reflect accelerated disease progression related to poor nutritional status rather than Almonertinib-specific resistance. Moreover, mild to moderate anxiety was observed in all patients receiving Almonertinib, underscoring the importance of incorporating psychological support in cancer care.
Indexed as
Identifiers
41045332What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.